Stock Watch 2026-10-15: Pfizer (PFE)

天天是周末
10-16 17:16

Company Background in Brief

$PFE 20261218 30.0 CALL$ is one of the world’s largest biopharmaceutical companies, selling medicines and vaccines in oncology, immunology, rare disease and infectious disease. As COVID-related sales fade, the company is rebuilding growth through acquisitions such as Metsera and a deeper oncology pipeline.

Why It's on the Watchlist (Key Growth Catalysts)

  • Pfizer’s newer medicines are growing fast. Its newer medicines grew 18% in the second quarter and brought in about $3.2 billion. Two cancer drugs, Padcev and Lorbrena, led the way with growth of 23% and 37%.

  • The patent worry is getting smaller. A patent stops other companies from selling cheap copies of a drug. Pfizer made deals with three generic drug makers, so its heart drug Vyndamax should be protected in the US until June 2031, although other lawsuits could still change this. Pfizer now expects Vyndamax sales to stay fairly steady from 2028 to mid-2031.

  • Important test results may come soon. Pfizer is expected to release results this quarter from a late-stage prostate cancer drug trial and from a weight-loss drug combination trial. Good results could push the stock up, and bad results could push it down.

Technical Setup & Trade Execution Plan

Pfizer has recently broken above its local resistance level at $29.10, signaling a bullish continuation within its upward channel and supported by a positive MACD bullish crossover. To capitalize on the upcoming earnings momentum and near-term upside while keeping risk defined, a long call option with ~60 days to expiration provides an optimal balance between premium efficiency and sufficient duration. (Eg. PFE 20261218 30.0 CALL @ $0.91)

# 💰Stocks to watch today?(16 October）

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（2）

  • Top
  • Latest
  • CarterSilas
    ·10-16 18:44
    Padcev and Lorbrena are doing the heavy lifting, but access in newer markets is what sets the real ceiling here. If that rollout stays slow, the 18% newer-meds growth gets harder to sustain
    Reply
    Report
  • ColinThorndike
    ·10-16 18:44
    29.10 breakout with a MACD bull cross is clean. What matters more now is whether trial readouts hit before IV gets too rich
    Reply
    Report